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Introduction
A dramatic decline in the incidence and mortality of gastric cancer (GC) has been observed in recent decades; howev-
er, this ominous disease still prevails as the fourth most 
frequently occurring malignancy as well as the second cause of 
cancer-related death worldwide.1 The problem is most conspicu-
ous in developing countries, particularly in Asian countries, where 
75% of all GC occur.1–3 In Iran, GC is an important healthcare chal-
lenge with 10000 incident cases and 8000 deaths per year.4 Ardabil 
Province in Northwest Iran has the highest incidence of GC in Iran 
and one of the highest rates of this cancer in the world, with age-
standardized incidence rates (ASR) of 51.8 in men and 24.9 in 
women. Recent reports suggest that despite the mentioned world-
wide trend, the rate of GC is still increasing in Ardabil.5–9
While Helicobacter pylori (H. pylori) has been accepted as a 
GH¿QLWLYH FDUFLQRJHQ10 an inconsistency between its prevalence 
and cancer occurrence called “The African Enigma” has been ob-
served. This phenomenon refers to the lower risk of GC among 
some Asian and African populations, despite substantially high 
rates of H. pylori infection.10–14 These observations indicate that 
although H. pylori is necessary for the development of GC, it is not 
VXI¿FLHQWfor it. This suggests a prominent role for other GC risk 
factors and undermines the reliability of H. pylori preventive and 
eradication strategies in adult subjects.
GC is an insidious disease, often manifesting its symptoms at an 
advanced stage when few therapeutic options are available with 
HYHQOHVVHI¿FLHQF\7KHsluggish process, known as Correa’s cas-
cade15 passes through a series of intermediate stages (precancer-
ous lesions) before reaching full-blown malignancy. These pre-
cancerous lesions occur in the following order: gastritis, atrophy, 
intestinal metaplasia (IM), and eventually dysplasia. Establishing 
a screening program has always been of interest in the case of GC 
and these precancerous lesions may prove outstanding candidates 
for this purpose. Therefore, we have conducted a current popula-
tion-based, follow-up survey to investigate the role of precancer-
ous lesions in GC mortality as well as identifying individuals at 
high risk of GC in an unselected general population living in an 
area with a high prevalence of H. pylori infection west of Asia.
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Materials and Methods
Study environment 
Participants were selected from two major regions of Ardabil 
Province, namely the townships of Ardabil and Meshkinshahr. We 
used a simple random household selection in urban and rural ar-
eas. Subsequently, we selected a participant aged 40 years or more 
who met the inclusion criteria from each family. If the criteria for 
selected participants were not met, the adjacent neighbor to the 
right was considered as a choice for study participation. Exclusion 
criteria were participant refusal for any reason, previous history of 
clinical workup for gastrointestinal (GI) disorders (except for mild 
V\PSWRPVRIG\VSHSVLDZKLFKHQWDLOHGQRGH¿QLWHGLDJQRVLVDQG
required no medical therapy), pregnancy, and/or cardiopulmonary 
diseases. We provided thorough and clear information to all par-
ticipants regarding the potential EHQH¿WVDQGULVNVRIWKHVWXG\DQG
all participants expressed their voluntary, informed consent in written. 
A total of 1011 individuals accepted the conditions of the study 
and each consented to an endoscopy procedure. The clinic is the 
major provider for GI diagnostic and therapeutic services in Ard-
abil Province. All subjects were free to refer to Aras Clinic or any 
other physician or clinic for gastrointestinal workups, if necessary.
Baseline assessment
The participants were interviewed by trained physicians about 
their demographics, lifestyle habits, tobacco, alcohol or drug use, 
history ofXSSHU*,FDQFHULQ¿UVWGHJUHHUHODWLYHVDQGKLVWRU\RI 
GI symptoms. 
Subsequently, each participant underwent an upper GI endoscopy 
following a standardized protocol. Biopsy specimens were obtained 
from the incisura angularis, the lesser and greater curvatures of the 
antrum, the lesser and greater curvatures of the corpus, and the car-
dia. In addition, biopsy was taken from any visible lesions noted dur-
ing endoscopy. Specimens from the incisura angularis were used for 
rapid urease test to detect H. pylori infection. All biopsies were ori-
HQWHGRYHUVPDOOSLHFHVRI¿OWHUSDSHUDQG immediately submerged 
in neutral buffered formalin in appropriately labeled containers. 
7KHSURFHVVRIWLVVXHRULHQWDWLRQ¿[DWLRQODEHOLQJDQGUHFRUGLQJ
was supervised by the pathologists in charge. Histological diagno-
ses were made using 3 μm thick sections stained by the hematoxy-
lin and eosin method, and read by three pathologists experienced 
in gastrointestinal pathology. The pathologists were blinded to the 
endoscopic and clinical¿QGLQJV7KHKLVWRORJLFDOUHVXOWVZHUHFDW-
egorized based on The Updated6\GQH\&ODVVL¿FDWLRQRI*DVWULWLV16 
$VFHUWDLQPHQWRIGHDWKGXHWRJDVWULFFDQFHU*&GXULQJIROORZXS
At the start of the cohort study, we established a population-based 
cancer and death registry in Ardabil Province in collaboration with 
the International Agency for Research on Cancer (IARC) and the 
Ardabil University of Medical Sciences.4,17 From the year 2000 
onwards, data from these registries has been searched regularly to 
provide the time and cause of death of the participants, including 
cancer-related events. As for participants not registered in these 
systems, trained physicians contacted participants or their next 
of kin for health information. If the cause of death was uncertain, 
IXUWKHUDVVHVVPHQWVZHUHXQGHUWDNHQZLWKXVHRIDPRGL¿HGYHU-
sion of the WHO adult verbal autopsy.18 Trained staff collected 
WKHDYDLODEOHPHGLFDOGRFXPHQWVRIWKHSDUWLFLSDQWVDQGWKH¿QDO
cause of death was determined by two physicians who indepen-
dently reviewed the collected medical records and verbal autopsy 
forms. The UHVXOWVZHUHFRQ¿UPHGE\WZRDGGLWLRQDOLQWHUQLVWV
The Medical Ethics Committee of the Digestive Disease Re-
search Centre of the Tehran University of Medical Sciences ap-
proved the protocol of this study.
Data analysis
The descriptive data are presented as frequencies and means ± 
standard deviations (SD). The differences between groups were 
analyzed with a t-test for continuous variables and with a Chi-
square test for categorical variables. Entry time was GH¿QHG DV
the enrollment date. End of follow-up was GH¿QHGDVWKHGDWHRI
GC-related death, censoring, or the end of the follow-up (January 
1, 2013), whichever FDPH¿UVW8QLYDULDWHDQGPXOWLYDULDWH&R[
proportional hazard regression analyses were performed to assess 
the association between GC mortality and baseline precancer-
ous lesions and risk factors. The magnitudes of associations are 
presented as hazard ratios (HR) and the corresponding 95% con-
¿GHQFHLQWHUYDOV&,$JHZDVFODVVL¿HGLQWRWKUHHFDWHJR-
ries (±±DQGRUDERYHZKHUHDVWKH¿UVWFDWHJRU\
was the reference group. Histological changes in each individual 
were determined according to the highest level of change [normal, 
chronic gastritis, atrophic gastritis (AG), IM, or dysplasia] ob-
served in the biopsy reports. All analyses were performed using 
SPSS statistics software version 19 (IBM Corporation, NY, USA). 
P values of <0.05 ZHUHFRQVLGHUHGVWDWLVWLFDOO\VLJQL¿FDQW
Results
We followed 1011 participants (48.9% men) for an average of 
119.3 months (range: 10 to 144 months). During that time, 146 
(14.4 %) subjects died and 49 (4.8 %) were lost to follow-up. Of 
these, 40 (3.95%) died of GC. The person-time mortality rate due 
to GC was 3.95 per 1000 person-years. 
The cohort participants had a wide range of histological and en-
doscopic abnormalities other than cancer at the baseline measure-
ment (Table 1). &KURQLFJDVWULWLVHLWKHU01RU301LQ¿OWUDWLRQ
was the main KLVWRORJLFDO¿QGLQJ LQ   VXEMHFWV7KH
most advanced pathological changes were AG in 333 (33.8%) and 
IM in 176 (17.9%) cases. Only 20 (2.0%) people had gastric bi-
opsy specimens ZLWKFRPSOHWHO\QRUPDOKLVWRORJ\:HGLGQRW¿QG
any cases of dysplasia in our patients.
Endoscopically, 389 (38.7%) participants had some degree of 
JDVWURHVRSKDJHDO UHÀX[GLVHDVH *(5'(YLGHQFHRI DQactive 
duodenal ulcer (DU) was found in 19 (1.9%) and GU was found 
in 30 (3.0%) participants. There were no endoscopic abnormalities 
in the remaining 566 (56.4%) subjects. Table 1 shows detailed in-
formation of the main demographics, risk factors, histological and 
HQGRVFRSLF¿QGLQJV
Table 2 shows the results of the Cox proportional hazard mod-
els. The univariate analysis showed an increasing trend of cancer 
mortality by age. Smoking, family history of GC, and the presence 
RI*8ZHUHVLJQL¿FDQWGHWHUPLQDQWVRIGC. Among histological 
changes, two well-known risk factors, AG and IM, dramatically 
increased the risk of death due to *&:H IRXQGQR VLJQL¿FDQW
increase in the risk of GC mortality by gender, H. pylori infection, 
GERD or DU (Table 2).
:KHQZH¿WWHGDPXOWLYDULDWHKD]DUGPRGHOE\including all life-
style demographic, endoscopic and histological factors, the HR 
DQGWKH&,VRI*&GHDWKUHPDLQHGVLJQL¿FDQWIRUthe 51–60 
DJHJURXS±DQGDJHJURXS±Other 
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risk factors, including a family history of GC, the presence of a 
*8DQGVPRNLQJZHUHVLJQL¿FDQWIDFWRUVZLWKsmall changes in the 
magnitude of the association. Again, two main histological precan-
FHURXVOHVLRQVZHUHVLJQL¿FDQWO\DVVRFLDWHGZLWKDKLJKHUrisk of 
GC compared to subjects who were either entirely normal or only 
had chronic gastritis. The HR and the 95% CIs were 7.4:1.6–33.8 
for AG and 23.6:5.5–10.2.3 for IM (Table 2). 
We found that the joint effect of individual risk factors and one of 
the precancerous lesions increased the HR to 46.5:10.8–198.6 for 
the combination of a precancerous lesion with a family history of 
GC, 27.6:6.5–116.4 for the combination of a precancerous lesion 
and smoking, and 25.1:6.3–105.3 for the combination of a precan-
cerous lesion and age > 50 years. 
Discussion
This study was conducted in a relatively large group of appar-
ently healthy participants who resided in an area with a high in-
cidence of GC, nearly all of whom were infected with H. pylori. 
The presence of a precancerous lesion at baseline was a strong pre-
dictor of GC mortality over long term follow-up, but age, family 
history of GC, smoking, and GU independently contributed to this 
risk. Gender, education, DU, GERD, and H. pylori infection did 
QRWVLJQL¿FDQWO\DIIHFWWKH risk of GC death. 
Most previous studies that assessed the role of precancerous le-
sions used GC incidence rather than mortality as the outcome. 
González et al. conducted a 12.8 year follow-up in a high inci-
dence area of Spain on symptomatic patients who referred to the 
hospital for gastroscopy. That study reported an incidence rate of 
0.35% per year.19 A Japanese study of male cases found a person-
year incidence rate of 0.37% over a mean follow-up of 7.8 years.20 
Another study conducted in a Chinese high-risk area that enrolled 
only rural subjects without data on the history of GI disorders, 
reported an average incidence of 0.22% after a follow-up of 4.5 
Baseline characteristics
+LVWRORJLFDO¿QGLQJVn) (QGRVFRSLF¿QGLQJVn) Total (n)
Normal
(20)
CG

AG
(333)
IM

Normal 

'8
(19)
*8
(30)
GERD
(389)
Total
(1011)
Male (%) 30.0 50.3 42.9** 56.3** 42.9 77.8* 60* 55.5* 48.9
Mean age in years (SD) 53.7(13.2)
51.8
(9.9)
52.7
(9.5)
57.5
(9.8)
53.1
(9.9)
55.5
(11.0)
53.1
(9.5)
55.2
(10.1)
53.1
(9.9)
H. pylori infection (%) 50.0* 89.1 95.5 83.0 87.3 94.4 93.3 88.9 88.2
Family history of GC (%) 25.0 18.7 20.7 26.7 20.4 16.7 50* 18.8 20.6
Positive smoking history (%) 25.0 38.9 36.9 45.5 39.4 61.1 46.7 37.0 39.1
Alcohol (%) 5 4.2 1.8 5.1 3.1 5.6 6.7 3.6 3.5
Illiterate (%) 79.2 70.3 79.6 81.8 76.5 83.3 70.0 74.6 75.7
GC= gastric cancer, CG= chronic gastritis, AG= atrophic gastritis, IM= intestinal metaplasia, DU= duodenal ulcer, GU= gastric ulcer, GERD= 
JDVWURHVRSKDJHDOUHÀX[GLVHDVHP < 0.0001 for selected item vs. otherwise, **P < 0.0001 for selected item vs. otherwise.
Table 1. Baseline characteristics of cohort participants.
Baseline characteristics GC cases (n)
8QLYDULDWH Multivariate
HR 95% CI HR 95% CI
Gender
Female 17 1 —
Male 23 1.5 0.8–2.8 — —
Age (years)
40–50 7 1 — 1 —
51–60 9 4.4 1.3–14.2 3.9 1.2–13.0
 24 11.0 3.8–31.7 8.0 2.7–23.5
H. pylori infection No 8 1 — — —
Yes 32 2.3 0.5–9.6
Family history of GC
No 14 1 — 1 —
Yes 26 7.2 3.4–14.1 6.5 3.2–13.0
Positive smoking history No 8 1 1 —
Yes 32 5.6 2.6–12.3 6.0 3.0–12.9
+LVWRORJLFDO¿QGLQJ
Normal/gastritis 25 1 — 1 —
Atrophic gastritis (AG) 24 8.6 1.9–38.4 7.5 1.6–33.8
Intestinal metaplasia (IM) 18 30.9 7.3–131.4 19.4 4.5–83.0
Duodenal ulcer (DU)
No 20 1 — — —
Yes 20 1.5 0.2–10.8 — —
Gastric ulcer (GU)
No 9 1 — 1 —
Yes 31 9.1 4.0–20.1 6.0 2.4–14.0
*DVWURHVRSKDJHDOUHÀX[
disease (GERD)
No 21 1 — — —
Yes 19 1.3 0.7–2.5 — —
Table 2. 5LVNRIJDVWULFFDQFHU *& UHSUHVHQWHGDVKD]DUG UDWLRV +5DQGFRQ¿GHQFH LQWHUYDOV &, LQXQLYDULDWHDQGPXOWLYDULDWH&R[
regression analyses after follow-up.
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years.21 We found a GC mortality rate of 3.95% during the follow-
up and showed that the presence of IM and AGVLJQL¿FDQWO\LQ-
creased mortality due to GC. The frequencies of AG and IM in the 
baseline assessments of our study participants were less than those 
in other studies. This may be related to the population-based nature 
of the study as most previous studies were conducted in hospital 
settings and on patients who presented with GI symptoms. 
The relationship between peptic ulcer disease and GC is currently 
under debate. A previousVWXG\KDVVKRZQDVLJQL¿FDQWDVVRFLDWLRQ
between the presence of a GU and GC, but their subjects were 
drawn from hospitalized patients who had severe GI complications 
such as bleeding or perforation or those who had received H. pylori 
eradication therapy.22,23 Our study showed that the presence of a 
SUHYLRXVO\XQGLDJQRVHG*8LPSRVHGDVLJQL¿FDQWULVNWRPRUWDOLW\
due to GC later in life. This might support the common mechanis-
tic link of GU and GC through AG. 
Although the proportion of male patients who died of GC in our 
study was higher than females, the difference was not statistically 
VLJQL¿FDQW 0DOH SUHGRPLQDQFH RI JDVWULF DGHQRFDUFLQRPD KDV
been described in a study that used the Scottish Cancer Registry 
records.24 A delay in the development of intestinal type adenocar-
cinoma in middle-aged women might explain the male predomi-
nance. Another study has suggested that female sex hormones 
might induce some degree of protection against GC.25 González 
et al. reported a higher risk of GC for males; however, this risk 
estimateZDVQRWVLJQL¿FDQWDIWHUDGMXVWLQJIRURWKHUULVNIDFWRUV19 
/DFNRIDVLJQL¿FDQWDVVRFLDWLRQEHWZHHQPDOHJHQGHUDQGWKH risk 
of GC in our regression analyses might be partly related to the 
masking effects of other risk factors such as smoking, AG and IM. 
The robust role of family history in the risk of GC is convincing, 
although most of the evidence has come from case-control stud-
ies.26 In our cohort study, we found that a family history of GC 
at the baseline measurement in a healthy population was strongly 
associated with an increased risk of GC-related death. One report 
reviewed 15 case-control studies of family history and GC, all of 
which indicated a positive relationship between these parameters, 
with risk ratios that ranged from 1.5- to 3.5-fold.27 This has been 
attributed to genetic factors, in addition to the environmental con-
ditions presumably shared by members of same family, which re-
sult in a familial clustering of GC. A dramatically increased risk of 
GC mortality in our participants with a previous or current history 
of smokingZDVDQRWKHU¿QGLQJFRQVLVWHQWZLWKSUHYLRXV¿QGLQJV
from the same population and other investigations that recruited 
different populations and various study designs.9,28 Of note, in our 
study the effect of these risk factors on GC mortality was indepen-
dent from the histological changes present at baseline This might 
suggest that these factors have an impact on the progression of pre-
cancerous lesions to GC incidence and death. 
H. pylori infection did not increase GC mortality in our subjects. 
Similarly, González  et al.19 reported a 67.2% H. pylori infection 
rate amongWKHLUVWXG\SRSXODWLRQZKLFKGLGQRWKDYHDVLJQL¿FDQW
effect on GC incidence. A lower prevalence of H. pylori infection 
DQGGHFOLQLQJQRQVLJQL¿FDQW+5ZHUHUHSRUWHGLQWKHPRUH ad-
vanced lesions in their study which might be because these lesions 
created unfavorable conditions for helicobacter survival and thus 
favored the clearance of the infection.19 The gradual disappearance 
of H. pylori in gastric mucosa saturated with advanced precancer-
ous lesions has previously been reported in a Japanese population 
with a very high risk of GC.29 Another possible explanation was 
related to the very high H. pylori infection rate and the consequent 
chronic gastritis in both studies, which seriously reduced the pow-
HURIWKHVWXGLHVWR¿QGDQ\VLJQL¿FDQWDVVRFLDWLRQ. This was sup-
SRUWHGE\ WKHVLJQL¿FDQWO\ ORZHU UDWHRI LQIHFWLRQ in individuals 
with normal baseline histology. Finally, based on previous reports, 
a remarkable fraction of the GCs in Ardabil arise from the cardia, 
which is not entirely related to H. pylori.9 The lack of accurate data 
on tumor location in the current study does not allow us to perform 
separate analyses for cardia and non-cardia GCs.
The lackRIDVWDWLVWLFDOO\VLJQL¿FDQWUROHIRUH. pylori infection in 
gastric carcinogenesis in this population is challenging. We believe 
that our results further represent the causal relationship between 
H. pylori infection and premalignant lesions. Both AG and the IM 
of gastric mucosa (particularly those in non-cardia locations) are 
strongly associated with H. pylori infection.30,31 As the other causes 
of AG (including autoimmune AG) are extremely rare, most cases 
can be considered long-term consequences of H. pylori infection 
regardless of their cross-sectional test results. A meta-analysis of 
seven randomized trials from high risk areas of Eastern Asia has 
suggested that H. pylori eradication reduces GC risk only in those 
treated at the earlier phases of carcinogenesis and before the de-
velopment of pre-neoplastic lesions.32 This strategy is not straight-
forward in areas like Ardabil with very high H. pylori infection 
rates. In these regions, most patients are infected at early ages, and 
the majority of the infected subjects are asymptomatic, thus rou-
tine testing and therapy may not be possible or appropriate. Mass 
eradication therapy in the general population is also not acceptable 
due to the side effects and the development of antibiotic-resistant 
microorganisms. An important breakthrough would be the devel-
opment of an effective vaccine against H. pylori infection. Even if 
such a vaccine becomes available, its administration will be useful 
only at the very early ages and it will still be necessary to have 
an appropriate secondary prevention strategy for those already in-
fected.33,34 
This population-based study has the advantage of studying a 
large number of asymptomatic individuals who were followed for 
a relatively long time. The cohort nature of the study and the stan-
dardized endoscopy procedure with an adequate target biopsy of-
fered the opportunity to have unbiased estimates of effect size for 
each of the major risk factors. 
One limitation of our study LV WKH ODFNRIVXI¿FLHQW UHFRUGVRI
histological sub-types of adenocarcinoma and reliable tumor lo-
calization. As previously discussed, the proportions of intestinal 
to diffuse subtypes of adenocarcinoma and cardia to non-cardia 
sub-sites have a great impact on the interpretation of associations 
between cancer risk and potential risk factors. Another major limi-
tation is that as a cohort study with a long term follow-up, there is 
a relativelyVPDOOQXPEHURI*&HYHQWV7KXVZHFRXOGQRW¿QG 
VLJQL¿FDQWGLIIHUHQFHVEHWZHHQFHUWDLQJURXSVHJPDOHVYHUVXV
females) and the CI are rather wide for some variables. 
In summary, we, through a population-based cohort study, have 
shown that the presence of precancerous lesions dramatically in-
creases the rateRI*&GHDWK,QSDUWLFXODURXU¿QGLQJVHPSKDVL]HG
the less recognized role of silent GU as independent risk factors for 
*&2XUVWXG\FRQ¿UPHGWKHLQGHSHQGHQWUROHRIDGYDQFHGDJH, 
smoking, and positive family history in GC progression and mor-
tality. We have proposed that a combined assessment of environ-
mental risk factors, family history and precancerous lesions might 
be useful to identify high-risk individuals in GC early detection 
programs. Such combined assessments can also assist in the design 
of an interventional trial based on a combination of non-invasive 
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0%RUHLUL)6DPDGL$(WHPDGLHWDO
tests, such as pepsinogen and the urea breath test, recognize candi-
dates for H. pylori eradication in infected subjects without precan-
cerous lesions, and identify people at high risk of GC.34–36
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